

SUMMARY OF REQUEST

DATE: November 17, 2021

FACILITY: Broward Health Medical Center

PROGRAM/PRODUCT LINE: Lab-Microbiology

REQUEST: The Microbiology Department is requesting approval to enter into a new cost per test agreement with current vendor, bioMerieux, for blood culture identification (ID) and antibiotic susceptibility test (AST).

PURPOSE: Results determine the antibiotic treatment that is most appropriate for a specific organism or group, the infectious agent, the site of infection and tracks any changes in bacterial resistant organisms.

CAPITAL REQUIRED: None

FISCAL IMPACT: FY 2022-2027

BUDGET STATUS: Budgeted

LEGAL REVIEW: The contract is subject to General Counsel's review and approval as to legal form and conditioned on no material changes in the approved business terms.



APPROVED: Shane Strum 11/15/2021 16:09 EST **DATE:** _____
Shane Strum President/CEO BH

MEMORANDUM

TO: Board of Commissioners

FROM: Shane Strum, President/CEO BH

DATE: November 17, 2021

SUBJECT: The Microbiology Department is requesting approval to enter into a new cost per test agreement with current vendor, bioMerieux, for blood culture identification (ID) and antibiotic susceptibility test (AST)

BACKGROUND

BioMerieux is the market leader in automated bacterial identification and antibiotic susceptibility testing. Clinicians use antibiotic susceptibility test results to help determine the most appropriate treatment for the infection and the individual patient. Antibiotic susceptibility testing (AST) is essential to adapt the patient's antibiotic treatment and fight antibiotic resistance. ID/AST tests also play a role in epidemiological monitoring, making it possible to track changes in antimicrobial resistance patterns in healthcare settings. This five year Cost Per Test Agreement, which includes equipment and services, comes with an enhanced warranty and full service coverage on all equipment through the term of the agreement. The semi-annual commitment of 72,000 is 80% of the current volume to ensure compliance over the next five years. Removal of any existing equipment, after validation of new equipment, and 24/7 technical and professional support are added values upon execution.

ACTION/PROJECT DESCRIPTION

The Microbiology Department is requesting approval to enter into a new cost per test agreement with current vendor, biomerieux, for blood culture identification (ID) and antibiotic susceptibility test (AST)

FINANCIAL/BUDGETARY IMPACT

The five year proforma shows a \$2,966,965.43 spend for the system beginning in FY22. The breakout is as follows:

- FY22-\$558,737.40
- FY23-\$558,737.40
- FY24-\$586,674.27
- FY25-\$616,007.98
- FY26-\$646,808.38

JUSTIFICATION

An integral part of clinical decision-making, identifying bacteria and assessing their response to antibiotics is increasingly important due to the rise in multidrug resistant bacteria. A health system of our magnitude would need to rely on automated technology that can provide fast and reliable results which can improve patient care, manage outbreaks, and fight health-care associated infections. With the broad offerings and fully integrated platforms from bioMerieux BH can remain at the forefront of testing and identifying microorganism's genus and species in just a few minutes.

STAFF RECOMMENDATION

Therefore, it is requested that the Board of Commissioners of the North Broward Hospital District authorize the District to enter into a 5-year Microbiology Department cost per test agreement with current vendor, bioMerieux, for blood culture identification (ID) and antibiotic susceptibility test (AST), for an estimated cost of \$2,966,965.43.